Vascular endothelial growth factor (VEGF)- and VEGF receptor 2 (VEGFR2)–mediated angiogenesis contribute to the pathogenesis of HCC [15], making this signaling pathway a possible therapeutic target. Here, KDR is linked to hepatocellular carcinoma.